Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23rd EADV Congress, Amsterdam, the Netherlands, on 9th October 2014
Chairperson: Christopher E.M. Griffiths1
Speakers: Kristian Reich,2 Kenneth Gordon3
1. University of Manchester, Manchester, UK
2. Dermatologikum Hamburg, Hamburg, Germany
3. Northwestern University, Evanston, Illinois, USA
Disclosure: Prof Griffiths has been a paid adviser to and/or in receipt of research grants from Actelion, Abbvie, Pfizer, LEO Pharma, Galderma, Sandoz, Novartis, MSD, Amgen, Eli Lilly, Janssen, and Incyte. Prof Reich has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbvie, Amgen, Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novartis, Pfizer, Vertex, and Takeda. Prof Gordon has received research support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, and Merck, and has served as a consultant to Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Medac, Novartis, and Pfizer.
Acknowledgements: Writing assistance was provided by Dr Nicola Ray, Apothecom Scopemedical Ltd.
Support: The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily those of Novartis.
Citation: EMJ Dermatol. 2014;2:42-48.
The meeting provided a bench-to-bedside overview of the targeting of interleukin-17 (IL-17) for the treatment of psoriasis. Prof Kristian Reich described state-of-the-art research into the IL-17 pathway in psoriasis, and how this pathway is being targeted by a new generation of biologics. An overview of the most up-to-date Phase II and Phase III data available for agents targeting the IL-17 pathway, along with a discussion of the link between clinical efficacy and quality of life (QoL) outcomes, was presented by Prof Kenneth Gordon. Finally, Prof Christopher Griffiths discussed how the superior efficacy of the new anti-IL-17 biologics enables physicians to aim higher in terms of achievable clinical benefits for patients, reaching beyond the current accepted clinical standard of PASI 75 – a 75% reduction in symptoms on the Psoriasis Area Severity Index (PASI) – and to have a greater impact on patient QoL.